---
title: Optimize electrode placement using esketamine
nct_id: NCT06543563
phase: NA
status: RECRUITING
sponsor: Beijing Tiantan Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06543563"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06543563"
last_fetched: "2026-05-10T14:05:22.516Z"
source: "Parkinson's Pathways (curated)"
---
# Optimize electrode placement using esketamine

**Goal (in five words):** Optimize electrode placement using esketamine

**Official Title:** Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease（ASPIRE）：A Randomized Controlled, Double-blind Study

**Trial ID:** [NCT06543563](https://clinicaltrials.gov/study/NCT06543563)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Beijing Tiantan Hospital
- **Target Enrollment:** 102 participants
- **Start Date:** 2024-08-09
- **Completion Date:** 2025-12-31
- **Conditions:** PD - Parkinson's Disease, Deep Brain Stimulation, Esketamine
- **Interventions:** esketamine, normal Saline
- **Intervention Types:** DRUG

## Summary For Families

The goal is to find out whether using esketamine during microelectrode recording-guided subthalamic deep brain stimulation helps provide steady, safe sedation while keeping the brain signals surgeons use to place DBS leads accurate, which can improve surgery for Parkinson's motor symptoms. Esketamine is a fast-acting anesthetic that blocks NMDA receptors to give sedation and pain relief, it affects brain activity differently than levodopa which works on dopamine so it is used only during surgery rather than as a Parkinson's treatment, and the team will watch for blood pressure changes or brief hallucinatory effects during the operation. Eligible participants are adults 50 to 80 years old scheduled for bilateral STN-DBS with ASA grade II or III, and people with sleep apnea, BMI over 30, difficult airways, severe anxiety, major organ failure, or anesthesia allergies are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1.50-80 years old, ASA grade II-III; 2.Bilateral STN-DBS of patients with Parkinson's disease; 3.Signed informed consent.

Exclusion Criteria:

1. Obstructive sleep apnea;
2. BMI \> 30kg/m2;
3. Estimated difficult airway;
4. Severe preoperative anxiety;
5. Serious dysfunction of important organs (i.e. heart failure, renal or liver dysfunction)
6. A history of allergy to the anaesthetics.
```

## Locations (1)

- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Ruquan Han, MD,PhD — (CONTACT) — 8610-59976660 — ruquan.han@gmail.com
  - Ruquan Han, MD,PhD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Ruquan Han, MD,PhD — (CONTACT) — 8610-59976660 — ruquan.han@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06543563*  
*HTML version: https://parkinsonspathways.com/trial/NCT06543563*  
*Source data: https://clinicaltrials.gov/study/NCT06543563*